BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35359347)

  • 1. Screening for prostate cancer: a study on the free and total prostate specific antigen.
    Mediu R; Rama A; Mediu N
    Discoveries (Craiova); 2021; 9(4):e139. PubMed ID: 35359347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of early detection for prostate cancer in mass screening].
    Kato M; Tammbo M; Yoshimatsu T; Ohta M; Kinjyo M; Noda H; Watanabe K; Miyata A; Murata A; Miura I; Yoneda T; Yoshii M; Okegawa T; Kojima M; Sayama T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):23-9. PubMed ID: 11235139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
    Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml.
    Wu CT; Chuang CK; Chou CC; Chu SH; Chen HW; Chen CS; Chiang YJ; Liao SK
    Chang Gung Med J; 2000 Mar; 23(3):142-8. PubMed ID: 15641217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.